Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Western Ontario, Canada | OTHER |
| Synaptive Medical | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Using Synaptive Medical's BrightMatter™ products to better visualize and plan epilepsy surgeries by considering white matter tracts, and considering whether the technology results in improved clinical outcomes.
A common goal of focal brain resection is the removal of a lesion while preserving healthy eloquent tissues of the brain. One such eloquent area that is commonly aimed to be preserved are the white matter nerve fiber tracts which is critical of brain communication and function. This study aims to investigate whether the use of Synaptive Medical's BrightMatterTM technology can help neurosurgeons to better visualize and plan surgeries by considering the white matter tracts, and whether it results in improved clinical outcomes. This study will investigate the preservation of the optic radiations in anterior temporal lobectomy epilepsy surgeries.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control Group | No Intervention | Control Group (involvement of BrightMatter™ Plan (BMP)): Patients with temporal lobe epilepsy, who have been identified as candidates for anterior temporal lobe resection (ATLR) will be recruited. All epilepsy patients will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out . Primary outcomes will be assessed to identify the baseline incidence of visual of postoperative visual field deficits. | |
| Treatment Arm | Experimental | Treatment group (involvement of all three products BrightMatter™ Plan (BMP), BrightMatter™ Bridge (BMB), and BrightMatter™ Guide(BMG): A treatment group (prospective enrollment) that uses the interventional technology will be recruited based on the same eligibility criteria as control cohort. All epilepsy patients will have clinical MRI scans that include a DTI protocol. For this treatment group of patients, the BrightMatter system (BMB,BMP, and BMG) will be employed pre-operatively and intra-operatively for planning before and guidance during anterior temporal lobe resection (ATLR). Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out. Primary outcomes will be assessed to evaluate the effect of surgical planning and guidance with DTI tractography on outcomes, by comparison against the control cohort. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BrightMatter™ products | Device | BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images. BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan. BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively. |
| Measure | Description | Time Frame |
|---|---|---|
| Total volume of tract damage | Tract damage | Assessed between pre and post-operative visits (6 month follow-up). |
| Resection Zone | Identification of resected region | Assessed at surgical visit |
| Post-operative visual field testing | Outcome will be measured using a routine visual field testing procedure known as the Humphrey and Estermann perimetry test. | Assessed at post-operative visit (6 month follow-up) |
| Measure | Description | Time Frame |
|---|---|---|
| Total neurological planning time | Measured in hours | Assessed during planning phase of surgery, between both pre and post-operative visits (6 month follow-up). |
| Total OR time | Measured in hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andrew Parrent | Contact | 519-663-3707 | 33707 | andrew.parrent@lhsc.on.ca |
| Ali Khan | Contact | 519-931-5777 | 24280 | alir@robarts.ca |
| Name | Affiliation | Role |
|---|---|---|
| Andrew Parrent | London Health Sciences | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D004833 | Epilepsy, Temporal Lobe |
| ID | Term |
|---|---|
| D004828 | Epilepsies, Partial |
| D004827 | Epilepsy |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Assessed during surgical visit |
| Duration of hospital stay | Measured in # of days | Assessed during surgical visit up to 26 weeks. |
| Number of seizure free days | Measured in # of days | Assessed between surgical date until post-operative visit (6 month follow-up). |
| Total cost of surgery | Assessed through study completion, an average of 1 year. |
| Quality of life assessment | Measured using a standard epilepsy questionnaire known as the WHOQOL-BREF questionnaire (World Health Organization Quality of Life Assessment (WHOQOL-BREF)) | Assessed during surgical visit up to 26 weeks. |
| Functional impairment | Measured using a routine functional impairment test known as the Karnofsky performance scale | Assessed during surgical visit up to 26 weeks. |
| Morbidity and complications | Number of cases | Assessed through study completion, an average of 1 year. |
| Seizure control after surgery | Assessed using a routine seizure control test known as the Engel score, assessed by a neurologist/epileptologist | Assessed at surgical visit up to 26 weeks. |
| D009422 |
| Nervous System Diseases |
| D000073376 | Epileptic Syndromes |